Forte Biosciences reported earnings of per FBRX share on Nov 13, 2026, falling short of analysts' expectations by
| Report Date | Nov 13, 2026 |
|---|---|
| Forecasted EPS | -$ 0.90 |
| Last Year's EPS | -$ 1.19 |
| EPS YoY Change |
Out of the last 40 earnings reporting periods, Forte Biosciences beat analysts’ expectations 16 times and fell short of expectations 21 time(s). Forte Biosciences reported earnings per share of in the last report surpassing an estimated EPS of -$ 0.90 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 0.90 | -$ 0.99 | - | |
| Aug 11, 2026 | -$ 1.08 | -$ 0.97 | -$ 0.96 | |
| May 21, 2026 | -$ 1.16 | -$ 1.24 | -$ 1.37 | |
| May 11, 2026 | -$ 1.16 | -$ 1.24 | -$ 2.45 | |
| Mar 31, 2026 | -$ 1.42 | -$ 1.45 | -$ 4.54 | |
| Nov 14, 2025 | -$ 1.04 | -$ 0.99 | -$ 6.75 | |
| Aug 14, 2025 | -$ 1.21 | -$ 0.96 | -$ 4.00 | |
| May 15, 2025 | -$ 0.89 | -$ 1.37 | -$ 1.00 | |
| Mar 24, 2025 | -$ 4.55 | -$ 2.45 | -$ 6.50 | |
| Nov 14, 2024 | -$ 6.75 | -$ 4.54 | -$ 10.50 | |
| Aug 14, 2024 | -$ 4.00 | -$ 6.75 | -$ 8.00 | |
| May 13, 2024 | -$ 0.16 | -$ 4.00 | -$ 6.00 | |
| Mar 18, 2024 | -$ 0.28 | -$ 1.00 | -$ 4.50 | |
| Nov 13, 2023 | -$ 14.25 | -$ 6.50 | -$ 5.25 | |
| Aug 14, 2023 | - | -$ 10.50 | -$ 4.25 | |
| May 15, 2023 | - | -$ 8.00 | -$ 5.25 | |
| Mar 31, 2023 | -$ 0.16 | -$ 6.00 | -$ 13.50 | |
| Nov 14, 2022 | -$ 0.15 | -$ 4.50 | -$ 10.75 | |
| Aug 15, 2022 | -$ 0.17 | -$ 5.25 | -$ 9.00 | |
| May 16, 2022 | -$ 0.17 | -$ 4.25 | -$ 0.37 |
Forte Biosciences’s stock was trading at on Nov 12, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Aug 11, 2026 | -$ 0.97 | $ 76.82 | $ 76.78 | |
| May 21, 2026 | -$ 1.24 | $ 20.31 | $ 21.59 | |
| May 11, 2026 | -$ 1.24 | $ 24.02 | $ 24.29 | |
| Mar 31, 2026 | -$ 1.45 | $ 26.32 | $ 24.86 | |
| Nov 14, 2025 | -$ 0.99 | $ 13.84 | $ 14.49 | |
| Aug 14, 2025 | -$ 0.96 | $ 10.57 | $ 11.57 | |
| May 15, 2025 | -$ 1.37 | $ 7.60 | $ 7.85 | |
| Mar 24, 2025 | -$ 2.45 | $ 8.17 | $ 8.51 | |
| Nov 14, 2024 | -$ 4.54 | $ 5.67 | $ 5.84 | |
| Aug 14, 2024 | -$ 6.75 | $ 10.58 | $ 7.75 | |
| May 13, 2024 | -$ 4.00 | $ 18.63 | $ 17.00 | |
| Mar 18, 2024 | -$ 1.00 | $ 15.50 | $ 16.50 | |
| Nov 13, 2023 | -$ 6.50 | $ 11.00 | $ 9.75 | |
| Aug 14, 2023 | -$ 10.50 | $ 22.03 | $ 20.50 | |
| May 15, 2023 | -$ 8.00 | $ 26.25 | $ 26.25 | |
| Mar 31, 2023 | -$ 6.00 | $ 25.50 | $ 25.11 | |
| Nov 14, 2022 | -$ 4.50 | $ 25.75 | $ 25.00 | |
| Aug 15, 2022 | -$ 5.25 | $ 33.25 | $ 32.75 | |
| May 16, 2022 | -$ 4.25 | $ 29.50 | $ 30.25 | |
| Mar 31, 2022 | -$ 5.25 | $ 37.00 | $ 37.75 |
Forte Biosciences released its most recent earnings reports in November 2026, August 2026, May 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Forte Biosciences beat analysts’ expectations during the last earnings period by
